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Receptor activator of NF-κB ligand (RANKL) plays an essential role in osteoclast formation and bone resorption. 
Although genetic and biochemical studies indicate that RANKL regulates osteoclast differentiation by activating 
receptor activator of NF-κB and associated signaling molecules, the molecular mechanisms of RANKL-regulated 
osteoclast differentiation have not yet been fully established. We investigated the role of the transcription factor 
c-Jun, which is activated by RANKL, in osteoclastogenesis using transgenic mice expressing dominant-negative 
c-Jun specifically in the osteoclast lineage. We found that the transgenic mice manifested severe osteopetrosis due 
to impaired osteoclastogenesis. Blockade of c-Jun signaling also markedly inhibited soluble RANKL-induced 
osteoclast differentiation in vitro. Overexpression of nuclear factor of activated T cells 1 (NFAT1) (NFATc2/
NFATp) or NFAT2 (NFATc1/NFATc) promoted differentiation of osteoclast precursor cells into tartrate-resis-
tant acid phosphatase–positive (TRAP–positive) multinucleated osteoclast-like cells even in the absence of 
RANKL. Overexpression of NFAT1 also markedly transactivated the TRAP gene promoter. These osteoclasto-
genic activities of NFAT were abrogated by overexpression of dominant-negative c-Jun. Importantly, osteoclast 
differentiation and induction of NFAT2 expression by NFAT1 overexpression or soluble RANKL treatment were 
profoundly diminished in spleen cells of the transgenic mice. Collectively, these results indicate that c-Jun signal-
ing in cooperation with NFAT is crucial for RANKL-regulated osteoclast differentiation.
Introduction
The amount of bone remodeling is controlled by the balance 
between bone formation and bone resorption (1–3). Many 
osteopenic diseases, including osteoporosis, rheumatoid arthri-
tis, Paget disease, and lytic bone metastases of malignancies are 
characterized by progressive and excessive bone resorption by 
osteoclasts, which are multinucleated giant cells that originate 
from hematopoietic cells (2). A TNF family member, receptor 
activator of NF-κB ligand (RANKL), which is expressed as a mem-
brane-bound protein in osteoblasts and stromal cells, promotes 
the differentiation of osteoclast precursor cells into osteoclasts (4, 
5). Gene-targeted mice deficient in RANKL expression show severe 
osteopetrosis with complete absence of osteoclast formation (5). 
These findings indicate that RANKL is an essential factor respon-
sible for osteoclast differentiation.
RANKL mediates its biological effects through receptor activa-
tor of NF-κB (RANK), which is expressed in osteoclast precursors 
(6). RANK interacts with the intracellular molecule, TNF recep-
tor–associated factor 6 (TRAF6), which plays an important role 
in the activation of downstream signaling pathways, including 
NF-κB, p38 kinase, and c-Jun N-terminal kinase (JNK) (2). Tar-
geted disruption of RANK (6), TRAF6 (7, 8), or NF-κB (9) genes in 
mice induces osteopetrosis, indicating the indispensable roles of 
these molecules in regulating the differentiation and function of 
osteoclasts. Since treatment with p38 inhibitors suppresses osteo-
clastogenesis in vitro (10), p38 seems to be involved in controlling 
osteoclast differentiation.
RANKL also stimulates JNK, and subsequently elicits the activa-
tion of the transcription factor c-Jun (11). c-Jun forms activator pro-
tein-1 (AP-1) complexes with c-Fos, an essential transcription factor 
for osteoclast formation (12). These findings suggest a potential 
role of c-Jun signaling in osteoclasts. However, in contrast to NF-κB 
signaling, the physiological role of c-Jun signaling in RANKL-
induced osteoclast differentiation and the subsequent transcrip-
tional events that regulate osteoclastogenesis remain unclear.
In the present study, we investigated the role of c-Jun signaling in 
osteoclastogenesis and the molecular mechanisms in which c-Jun 
is involved. Our data demonstrate that activation of c-Jun signaling 
is essential for RANKL-regulated osteoclast formation in vivo and 
in vitro. Furthermore, we show that c-Jun regulates osteoclast dif-
ferentiation in cooperation with nuclear factor of activated T cells 
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(NFAT). Therefore, the coupling of c-Jun signaling with NFAT fam-
ily is crucial for transcriptional events during osteoclastogenesis.
Results
Since c-Jun–deficient mice are embryonic lethal (13), investigating 
the role of c-Jun signaling in osteoclasts using c-Jun–deficient mice 
is complicated. To evaluate the physiological role of c-Jun signaling 
in osteoclast differentiation in vivo, we generated transgenic mice 
(TRAP-DN–c-Jun TG) in which dominant-negative c-Jun lacking 
the transcriptional activation domain (14, 15) was expressed under 
control of the mouse tartrate-resistant acid phosphatase (TRAP) gene 
promoter, which is specific for the osteoclast lineage (16, 17). RT-PCR 
Figure 1
Osteopetrotic phenotype of TRAP-DN–c-Jun TG mice. (A) Expression of DN–c-Jun transgene in TRAP-DN–c-Jun TG mice. Total RNA isolated from 
brain (lanes 1 and 7), kidney (lanes 2 and 8), liver (lanes 3 and 9), lung (lanes 4 and 10), spleen cells (lanes 5 and 11), or BMMΦ (lanes 6 and 12) 
of wild-type (WT; lanes 1–6) and TRAP-DN–c-Jun TG (TG; lanes 7–12) littermate mice were subjected to RT-PCR analysis using specific primers 
for DN–c-Jun (top panel) or β-actin (bottom panel). (B) Appearance of wild-type and TRAP-DN–c-Jun TG littermate mice. No tooth had erupted in 
TRAP-DN–c-Jun TG mice. (C) Radiological analyses in TRAP-DN–c-Jun TG mice. TRAP-DN–c-Jun TG mice showed increased radiodensity of long 
bones, vertebrae, and jaw compared with wild-type littermates. (D) H&E and TRAP staining of long bones of WT or TRAP-DN–c-Jun TG littermate 
mice. Left panels, lower magnification (H&E, ×50; TRAP, ×100); right panels, higher magnification (H&E, ×100; TRAP, ×400). (E) Impaired osteoclasto-
genesis of TRAP-DN–c-Jun TG mice in vitro. Spleen cells isolated from wild-type or TRAP-DN–c-Jun TG littermate mice were incubated with M-CSF 
and sRANKL for 6 days, and TRAP+ multinucleated osteoclast-like (ocl) cells were counted. (F) Macrophage-like cell differentiation determined by 
NSE staining in the culture of spleen cells in α-MEM–10% FCS with M-CSF. (G) Osteoblast differentiation determined by ALP staining (left panel) or 
evaluated for ALP activity (right panel) in the culture of primary osteoblasts isolated from calvariae in α-MEM–10% FCS with BMP2.
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analysis indicated specific expression of dominant-negative c-Jun in 
the osteoclast lineage (Figure 1A). As shown in Figure 1B, the body 
size of TRAP-DN–c-Jun TG mice was much smaller than that of wild-
type littermates. Incisors and molars of TRAP-DN–c-Jun TG mice 
failed to erupt despite formation of tooth germs. TRAP-DN–c-Jun 
TG mice showed increased radiodensity of long bones, jaw bones, and 
vertebrae compared with control mice (Figure 1C). The bone marrow 
cavities of TRAP-DN–c-Jun TG mice were filled with unresorbed 
trabecular bones (Figure 1D). More importantly, TRAP staining dem-
onstrated very few osteoclasts in the long bones of TRAP-DN–c-Jun 
TG mice (Figure 1D). Consistently, osteoclast formation of spleen 
cells derived from TRAP-DN–c-Jun TG mice was markedly lower than 
that of wild-type littermates (Figure 1E). In contrast, the spleen cells 
of TRAP-DN–c-Jun TG mice differentiated into macrophage-like cells 
just as well as did those of wild-type mice (Figure 1F). The differen-
tiation of osteoblasts, which play a central role in bone formation, 
Figure 2
Inhibition of osteoclast differentiation by blockade of JNK activation. (A) Osteoclast differentiation of BMMΦ and RAW264 cells was determined 
by TRAP staining. (B) Lysates of BMMΦ or RAW264 cells were analyzed by immunoblotting using anti–phospho-JNK (anti–p-JNK), JNK1, phos-
pho–c-Jun (p–c-Jun), or c-Jun antibody. (C) Lysates of BMMΦ cells treated with sRANKL and SP600125 (5 μM) as indicated, were analyzed by 
immunoblotting using anti–phospho-JNK, JNK1, phospho–c-Jun, or c-Jun antibody. (D) Suppression of osteoclastogenesis by JNK inhibitor. Mouse 
bone marrow cells were incubated with M-CSF and sRANKL in the presence of DMSO or SP600125 (5 μM), and TRAP+ multinucleated osteoclast-
like cells were counted. Cont, control (E) The effect of SP600125 on osteoclastogenesis is reversible after 1 day. BMMΦ cells were incubated with 
M-CSF and sRANKL in the absence (left bar) or presence (middle and right bars) of SP600125 (5 μM). SP600125 was removed after 24 hours 
by washing carefully (right bar). After 6 days of incubation, TRAP+ multinucleated osteoclast-like cells were counted. (F) Lysates of RAW264 cells 
infected with control or dominant-negative–JNK1 (DN-JNK1) adenovirus were analyzed by immunoblotting using phospho–c-Jun, c-Jun, or anti-
JNK1 antibody. (G) Suppression of osteoclastogenesis by DN-JNK1. RAW264 cells infected with control or DN-JNK1 adenovirus were incubated 
with sRANKL, and TRAP+ multinucleated osteoclast-like cells were counted. (H) Inhibition of osteoclast differentiation by suppression of c-Jun 
activation. Mouse spleen cells infected with retroviruses carrying either luciferase siRNA (siLuc) or MKK7 siRNA (siMKK7) were incubated with 
M-CSF and sRANKL, and TRAP+ multinucleated osteoclast-like cells were counted. The cell lysates were analyzed by immunoblotting as indicated.
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appears to be intact in TRAP-DN–c-Jun TG mice (Figure 1G). Thus, 
TRAP-DN–c-Jun TG mice manifested typical osteopetrosis due to an 
impairment of osteoclastogenesis. These results show that c-Jun is an 
essential transcription factor for osteoclast differentiation in vivo.
To understand the molecular mechanisms by which c-Jun regu-
lates RANKL-induced osteoclastogenesis, we next examined the 
activation of JNK and c-Jun signaling in osteoclast precursors, bone 
marrow macrophage (BMMΦ) (18), and RAW264 cells (6) in the 
presence of soluble RANKL (sRANKL). Treatment with sRANKL 
induced differentiation of BMMΦ and RAW264 cells into TRAP+ 
multinucleated osteoclast-like cells (Figure 2A) and activated 
JNK1, JNK2, and c-Jun in these cells (Figure 2B). Treatment with a 
specific JNK inhibitor, SP600125 (19), profoundly abrogated the 
activation of JNK and c-Jun (Figure 2C), and markedly inhibited 
the formation of TRAP+ osteoclast-like cells induced by sRANKL 
in mouse bone marrow cultures (Figure 2D). The inhibitor was not 
acutely toxic to the cells, since its inhibitory effect was abrogated 
by washing it out of the cultures at 1 day (Figure 2E). These data 
suggest that sustained activation of JNK and c-Jun is necessary for 
RANKL-induced osteoclastogenesis.
To further investigate the importance of c-Jun signaling in 
RANKL-induced osteoclast differentiation, we interfered with c-Jun 
and upstream signaling to c-Jun using dominant-negative and small 
interfering RNA (siRNA) knockdown approaches. Overexpression of 
dominant-negative JNK1 abolished c-Jun phosphorylation (Figure 
2F) and markedly inhibited osteoclast differentiation of RAW264 
cells in response to sRANKL (Figure 2G). Likewise, siRNA-medi-
ated knockdown of MAPK kinase 7 (MKK7), the upstream kinase 
Figure 3
Requirement of c-Jun and c-Fos for RANKL-induced osteoclastogenesis. (A) Inhibition of AP-1 transcriptional activity by DN–c-Jun or DN–c-Fos. 
RAW264 cells were transfected AP-1 reporter construct together with DN–c-Jun or DN–c-Fos, and incubated with sRANKL. Luciferase activity in cell 
lysates was measured. (B) Suppression of osteoclast differentiation by DN–c-Jun. RAW264 cells infected with control or DN–c-Jun adenovirus were 
incubated with sRANKL for 6 days, and TRAP+ multinucleated osteoclast-like cells were counted. (C) Inhibition of osteoclast differentiation by sup-
pression of c-Jun expression. Mouse spleen cells infected with retroviruses carrying either luciferase siRNA or c-Jun siRNA (siJun) were incubated 
with M-CSF and sRANKL for 6 days, and TRAP+ multinucleated osteoclast-like cells were counted. The cell lysates were analyzed by immunoblotting 
using anti–c-Jun or anti–β-actin antibody. (D) Activation of ATF-2 by sRANKL. The lysates of RAW264 cells stimulated with sRANKL were analyzed by 
immunoblotting using anti–phospho–ATF-2 (anti–p-ATF-2) or anti–ATF-2 antibody. (E) No effects of DN–ATF-2 on osteoclast formation. RAW264 cells 
infected with control or DN–ATF-2 adenovirus were incubated with sRANKL for 6 days, and TRAP+ multinucleated osteoclast-like cells were counted. 
(F) Inhibition of osteoclastogenesis by DN-c-Fos. RAW264 cells infected with control or DN-c-Fos adenovirus were incubated with sRANKL for 6 
days, and TRAP+ multinucleated osteoclast-like cells were counted. (G) No induction of osteoclastogenesis by overexpression of c-Jun and c-Fos. 
RAW264 cells infected with control, TRAF6, or c-Jun/c-Fos adenovirus were incubated with or without sRANKL for 6 days, and TRAP+ multinucleated 
osteoclast-like cells were counted.
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for JNK, also indicated the necessity of c-Jun activation in osteoclast 
formation of spleen cells (Figure 2H). Furthermore, overexpression 
of dominant-negative c-Jun markedly suppressed sRANKL-induced 
transcriptional activation of AP-1 (Figure 3A) and osteoclast differ-
entiation of RAW264 cells (Figure 3B). Finally, suppression of c-Jun 
expression by siRNA consistently and markedly inhibited osteoclast 
differentiation in a primary culture system (Figure 3C). In contrast, 
dominant-negative mutant of activating transcription factor-2 
(ATF-2), which is also activated by sRANKL (Figure 3D), did not 
affect osteoclast differentiation of RAW264 cells (Figure 3E). Taken 
together, these data strongly suggest that c-Jun signaling specifically 
mediates the effect of RANKL and promotes osteoclastogenesis.
Since c-Jun regulates the transcription of target genes by form-
ing the AP-1 complexes with c-Fos, we determined the role of c-Fos 
in RANKL-induced osteoclastogenesis. As shown in Figure 3A, 
overexpression of dominant-negative c-Fos markedly blocked 
sRANKL-induced AP-1 transcriptional activity. The osteoclas-
togenic activity of sRANKL was also markedly inhibited by 
overexpression of dominant-negative c-Fos (Figure 3F). These 
data indicate that both c-Fos and c-Jun are required for RANKL 
to regulate osteoclast differentiation. However, we were unable to 
induce differentiation of RAW264 cells into osteoclast-like cells by 
overexpressing c-Jun together with c-Fos (Figure 3G), suggesting 
that complexes of c-Jun and c-Fos need a partner transcription fac-
tor or co-activator to promote osteoclastogenesis.
c-Jun/c-Fos complexes associate with NFAT family proteins, 
and subsequently regulate the transcription of specific genes 
in T cells and some other types of cells (20–22). Therefore, we 
investigated the involvement of NFAT in osteoclastogenesis and 
the relationship between RANKL signaling and NFAT. First, we 
evaluated the transcriptional activity of NFAT during osteoclast 
differentiation by performing a reporter assay using a luciferase 
reporter plasmid driven by tandem NFAT binding sites. In 
RAW264 cells differentiated into TRAP+ multinucleated cells by 
treatment with sRANKL, transcriptional activity of NFAT was 
markedly elevated compared with undifferentiated RAW264 cells 
(Figure 4A). Moreover, NFAT1 (NFATc2/NFATp) was expressed 
in BMMΦ, RAW264 cells, and differentiated osteoclasts (Figure 
4, B–D), and stimulation with sRANKL induced the nuclear local-
ization of NFAT1 in RAW264 cells (Figure 4C). Furthermore, 
overexpression of TRAF6, which mimics the effects of RANKL 
(Figure 3G), dramatically increased the transcriptional activity of 
NFAT1 (Figure 4E). These data suggest that RANKL signals acti-
vate NFAT1 function and consequently regulate osteoclastogen-
Figure 4
Activation of NFAT1 by RANKL signals and requirement of NFAT for osteoclastogenesis. (A) Activation of NFAT transcriptional activity during 
osteoclast differentiation. RAW264 cells incubated with or without sRANKL were transfected with a luciferase reporter construct containing three 
copies of NFAT-responsive elements. Luciferase activity in cell lysates was measured. TRAP (+), TRAP+ osteoclast-like cells treated with sRANKL. 
RLU, relative light units. (B) Expression of NFAT1 in BMMΦ cells. The lysates of BMMΦ cells were analyzed by immunoblotting using anti-NFAT1 
antibody. (C) Nuclear translocation of NFAT1 by sRANKL. RAW264 cells were stimulated with or without sRANKL, and cytoplasmic and nuclear 
extracts were analyzed by immunoblotting with anti-NFAT1 antibody. (D) Expression of NFAT1 in osteoclasts. Mouse spleen cells were incubated with 
M-CSF and sRANKL for 6 days and analyzed by immunostaining (upper panel) or immunoblotting (lower panel) using NFAT1 antibody. (E) Transcrip-
tional activation of NFAT1 by TRAF6. COS-7 cells were transfected with a luciferase reporter construct containing three copies of NFAT-responsive 
elements together with either NFAT1 or TRAF6, or both. Luciferase activity in cell lysates was measured. (F) Suppression of osteoclastogenesis by 
cyclosporin A. Mouse bone marrow cells were incubated with M-CSF and sRANKL for 6 days in the presence or absence of cyclosporin A (CsA) 
as indicated. TRAP+ multinucleated osteoclast-like cells were counted under a microscope. (G) Inhibition of osteoclastogenesis by NFAT inhibitor, 
VIVIT peptide. RAW264 cells infected with control or GFP-VIVIT adenovirus at 20 or 50 MOI were incubated with sRANKL for 6 days, and TRAP+ 
multinucleated osteoclast-like cells were counted.
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esis. To support this idea, treatment with cyclosporin A, a well-
known inhibitor for the calmodulin-dependent phosphatase, 
calcineurin, which dephosphorylates and activates the NFAT 
family (22, 23), strikingly inhibited osteoclast differentiation 
in mouse bone marrow cultures (Figure 4F). A more selective 
NFAT inhibitor, VIVIT peptide (MAGPHPVIVITGPHEE) tagged 
with green fluorescent protein (GFP-VIVIT) (23), markedly sup-
pressed osteoclast differentiation of RAW264 cells (Figure 4G). 
Collectively, these results suggest the importance of NFAT1 in 
RANKL-induced osteoclast differentiation.
To examine the importance of NFAT1 function in osteoclast 
differentiation, we overexpressed NFAT1 in RAW264 cells using 
adenoviral vectors. When overexpressed in RAW264 cells, NFAT1 
was able to translocate into the nucleus even in the absence of 
sRANKL (Figure 5A). Importantly, overexpression of NFAT1 pro-
moted differentiation of RAW264 cells or mouse spleen cells into 
TRAP+ multinucleated osteoclast-like cells (Figure 5, B and C). 
In parallel with this result, NFAT1 overexpression dramatically 
increased TRAP gene promoter activity (Figure 5D). A constitu-
tively active mutant of NFAT1, which lacks a negative-regulatory 
domain present in its N-terminal region, further increased the 
TRAP gene promoter activity (Figure 5D). In contrast, another 
mutant NFAT1 (ΔNC), which lacks the transactivation domains 
present in the N- and C-terminal regions, failed to increase TRAP 
gene promoter activity (Figure 5D). Analysis using serial-deletion 
mutants of the TRAP gene promoter and a DNA pull-down assay 
demonstrated that NFAT1 regulates TRAP gene promoter activity 
through the NFAT-binding element present at –523 to –507 in the 
TRAP gene promoter (Figure 5, E and F). Both basal and NFAT-
induced reporter activity were markedly increased by deletion of 
the –881 to –737 region, suggesting the presence of a negative-
regulatory element in this region, but decreased again by further 
removal of the –737 to –681 region (Figure 5E). Since the fold 
induction of luciferase activity by NFAT1 was similar between 
TRAP737-Luc and TRAP681-Luc, the –681 to –737 region may 
contain a positive-regulatory element that is independent of 
NFAT. Collectively, these data suggest that NFAT1 is an impor-
tant transcription factor that regulates osteoclastogenesis.
Recently, NFAT2 (NFATc1/NFATc) has been proposed as a target 
of RANKL and a crucial transcription factor for osteoclast differ-
entiation (24, 25). To understand the relationship between NFAT1 
and NFAT2 during osteoclastogenesis, we determined whether 
NFAT1 is involved in the regulation of NFAT2 expression. We 
found that overexpression of NFAT1 induced NFAT2 expression 
Figure 5
Induction of osteoclast differentiation by NFAT1 overexpression. (A) Cytoplasmic and nuclear extracts of RAW264 cells infected with NFAT1 
adenovirus were analyzed by immunoblotting with anti-NFAT1 antibody. (B) RAW264 cells were infected with NFAT1 adenovirus at 10, 20, or 50 
MOI, and TRAP+ multinucleated osteoclast-like cells were counted. (C) Mouse spleen cells infected with control or constitutively active NFAT1 
retrovirus were cultured with M-CSF, and TRAP+ multinucleated osteoclast-like cells were counted. (D) RAW264 cells were transfected with TRAP 
gene promoter fused to a luciferase reporter construct together with wild-type, constitutively active (CA) or ΔNC mutant of NFAT1. Luciferase 
activity in cell lysates was measured. (E) Requirement of putative NFAT-binding element present in the TRAP gene promoter (–523 to –507) 
for transactivation by NFAT1. RAW264 cells were transfected with serial-deletion mutants of the TRAP gene promoter together with or without 
NFAT1, and luciferase activities were measured. The sequence of the putative NFAT-binding element in the TRAP gene promoter is indicated. (F) 
Binding of NFAT1 to NFAT-binding element present in TRAP gene promoter (–523 to –507). Lysates of COS-7 cells transfected with or without 
NFAT1 were precipitated (Ppt) with the oligonucleotide containing NFAT-binding element (NFAT-BE) from the TRAP gene promoter, and analyzed 
by immunoblotting using anti-NFAT1 antibody. (G) The lysates of RAW264 cells infected with NFAT1 adenovirus or incubated with sRANKL were 
determined by immunoblotting with anti-NFAT2 antibody. (H) Induction of osteoclast differentiation by NFAT2 overexpression. RAW264 cells were 
infected with control or NFAT1 or NFAT2 adenovirus and determined by TRAP staining.
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in the absence of sRANKL (Figure 5G). In addition, overexpression 
of NFAT2 also induced osteoclast differentiation of RAW264 cells 
(Figure 5H). These data suggest that NFAT1 upregulates NFAT2 
expression during osteoclast differentiation.
To investigate the molecular mechanisms by which c-Jun regulates 
osteoclast differentiation, we next examined the functional relation-
ship between c-Jun and NFAT during osteoclast differentiation. 
As shown in Figure 6A, osteoclast-like cell formation induced by 
NFAT1 or NFAT2 was clearly enhanced by overexpression of c-Jun 
and c-Fos. In contrast, overexpression of either dominant-negative 
c-Jun or dominant-negative c-Fos markedly blocked osteoclast dif-
ferentiation of RAW264 cells induced by NFAT1 or NFAT2 (Figure 
6, B and C). These data suggest that the collaboration of c-Jun/c-Fos 
complexes and NFAT is important for the regulation of osteoclasto-
genesis. To verify the importance of the partnership between c-Jun 
and NFAT at the transcriptional level, we tested the effect of a fusion 
protein of JNK1 and MKK7 (MKK7-JNK1), which constitutively 
activates AP-1 (26), on TRAP gene promoter activity. Overexpression 
of MKK7-JNK1 alone was unable to transactivate the TRAP gene 
promoter (Figure 6D). On the other hand, overexpression of MKK7-
JNK1 enhanced the transactivation of the TRAP gene promoter by 
NFAT1 (Figure 6D). Moreover, overexpression of either dominant-
negative c-Jun or dominant-negative c-Fos blocked transactivation 
of the TRAP gene promoter by NFAT1 (Figure 6E). These results 
strongly suggest that functional cooperation between c-Jun and 
NFAT is necessary for the stimulation of osteoclast differentiation.
To further understand the importance of functional coopera-
tion between c-Jun and NFAT during osteoclast differentiation, 
we examined the ability of NFAT1 to induce osteoclastogenesis 
and NFAT2 expression in spleen cells isolated from TRAP-DN– 
c-Jun TG mice. Overexpression of NFAT1 induced osteoclast-
like cell formation and NFAT2 expression in spleen cells isolat-
ed from wild-type mice (Figure 7, A and B), but failed to induce 
osteoclast-like cell formation and NFAT2 expression in spleen 
cells of TRAP-DN–c-Jun TG mice (Figure 7, A and B). In addition, 
induction of NFAT2 by sRANKL was also abolished in spleen cells 
of TRAP-DN–c-Jun TG mice (Figure 7C). These results indicate 
that NFAT1–c-Jun cooperation is required for NFAT1 function 
and NFAT2 expression during osteoclast differentiation induced 
either by RANKL or by NFAT1 itself.
Discussion
Although genetic studies using gene targeting technology have 
clearly demonstrated that RANK, TRAF6, and NF-κB, which 
transduce the signals of RANKL, are essential molecules for 
osteoclast differentiation (2), the mechanisms by which RANKL 
regulates osteoclastogenesis have not been fully clarified and thus 
our overall understanding of osteoclast differentiation is incom-
plete. In particular, the role of MAPKs, including JNK and p38 
kinase, both of which are elicited by RANKL (11), in osteoclastogen-
esis is elusive. In the present study, we showed that transgenic mice 
expressing dominant-negative c-Jun exhibited osteopetrosis, most 
Figure 6
Partnership between c-Jun/c-Fos complexes and NFAT in osteoclast differentiation. (A) Enhancement of NFAT1- or NFAT2-induced osteoclas-
togenesis by overexpression of c-Jun and c-Fos. RAW264 cells were infected with adenoviruses as indicated and incubated for 6 days. TRAP+ 
multinucleated osteoclast-like cells were counted. (B and C) Suppression of NFAT1- or NFAT2-induced osteoclastogenesis by DN–c-Jun or 
DN–c-Fos. RAW264 cells were infected with NFAT1 or NFAT2 adenovirus (50 MOI) together with control, DN–c-Jun, or DN–c-Fos adenovirus 
(50 MOI), and TRAP+ multinucleated osteoclast-like cells were counted. (D) Cooperative role of AP-1 and NFAT1 in transactivation of TRAP gene 
promoter. RAW264 cells were transfected with TRAP gene promoter fused to luciferase reporter construct together with NFAT1, MKK7-JNK1, or 
both. Luciferase activity in cell lysates was measured 48 hours after transfection. (E) Suppression of NFAT1-induced TRAP gene promoter activa-
tion by DN–c-Jun or DN–c-Fos. RAW264 cells were transfected with the TRAP gene promoter fused to a luciferase reporter construct together 
with DN–c-Jun or DN–c-Fos. Luciferase activity in cell lysates was measured 48 hours after transfection.
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likely as the result of impaired osteoclastogenesis, because very few 
osteoclasts were present in the long bones of the transgenic mice 
and osteoclast progenitor cells isolated from the spleens of trans-
genic mice formed few osteoclasts in the presence of sRANKL. Con-
sistent with these data, we also found that the blockade of the JNK 
and c-Jun pathway by treatment with a JNK inhibitor, SP600125, 
suppressed osteoclast differentiation induced by sRANKL. In addi-
tion, sRANKL-induced osteoclast differentiation was markedly 
inhibited by overexpression of dominant-negative JNK1 or domi-
nant-negative c-Jun. Furthermore, suppression of c-Jun or MKK7 
expression using siRNA technology dramatically inhibited osteo-
clastogenesis. Collectively, our genetic and biochemical results indi-
cate that the activation of c-Jun is indispensable for RANKL-depen-
dent osteoclast differentiation of the progenitor cells.
Recent studies demonstrated that RANKL induced NFAT2 
expression in BMMΦ or RAW264 cells, and showed the neces-
sity of NFAT2 in osteoclastogenesis in vitro (24, 25). Most nota-
bly, introduction of NFAT2 promoted the differentiation of 
BMMΦ cells into TRAP+ osteoclast-like cells even in the absence 
of sRANKL (25). These findings provided evidence that NFAT2 
is an important transcription factor for osteoclast formation. To 
advance these previous studies, we investigated the molecular basis 
by which NFAT regulates osteoclastogenesis. We show here that 
overexpression of NFAT1, which is expressed in both osteoclast 
progenitors and mature osteoclasts, induces expression of NFAT2 
and osteoclast differentiation of RAW264 cells. Consistent with 
our results, Zhou et al. reported regulation of the NFAT2 gene 
promoter by NFAT1 in the T-cell lineage (27). We have also dem-
onstrated that induction of NFAT2 by NFAT1 overexpression or 
sRANKL treatment was markedly diminished in spleen cells iso-
lated from TRAP-DN–c-Jun TG mice. It is therefore likely that 
NFAT1 functions as the upstream regulator for NFAT2 during 
osteoclastogenesis and that c-Jun is necessary for NFAT1 to induce 
NFAT2 expression. More interestingly, we also clearly showed that 
osteoclastogenic activity of NFAT1 and NFAT2 was enhanced by 
overexpression of c-Jun and c-Fos, but inhibited by overexpression 
of either dominant-negative c-Jun or c-Fos, indicating that the 
partnership between c-Jun/c-Fos and the NFAT family is crucial 
for osteoclast differentiation. In support of this notion, we dem-
onstrated that overexpression of NFAT1 was unable to promote 
osteoclastogenesis in the spleen cells of TRAP-DN–c-Jun TG mice. 
Collectively, our results suggest that sequential activation of the 
NFAT family and cooperation between c-Jun and the NFAT family 
are important for RANKL-induced osteoclast differentiation.
The NFAT family is well known to be controlled by calcineurin, 
which dephosphorylates the NFAT family and subsequently 
induces its nuclear localization (20, 28). We have provided evi-
dence that the RANKL/TRAF6 signal activates NFAT function 
during osteoclast differentiation. First, treatment with sRANKL 
induced nuclear localization of NFAT1 in RAW264 cells. Second, 
treatment with sRANKL or overexpression of TRAF6 upregulated 
the transcriptional activity of NFAT1. Recently, two groups 
reported that, in osteoclasts, RANKL elicits intracellular Ca2+ 
elevation (25, 29), which is necessary for activation of calcineurin 
(22, 28). Taken together, it seems likely that RANKL activates the 
NFAT family through TRAF6 and calcineurin. To support this 
notion, Koga et al. reported the cooperative role of immunore-
ceptor tyrosine-based activation motif-harboring adapters with 
RANKL signaling (30). The discovery of a protein kinase that 
links TRAF6 to calcineurin might establish the mechanism by 
which RANKL controls the NFAT family.
Identification of the NFAT family as important transcrip-
tion factors for osteoclastogenesis provides a new therapeutic 
target for bone diseases such as osteoporosis or rheumatoid 
arthritis. As VIVIT peptide has been developed as an optimized 
peptide that inhibits the interaction between the NFAT family 
and calcineurin but does not affect the phosphatase activity of 
calcineurin (23, 28) the small peptide composed of only 16 amino 
acids is a more specific inhibitor for the NFAT family than FK506 
or cyclosporin A. Indeed, we have found that overexpression of 
GFP-VIVIT successfully blocks osteoclastogenesis induced by 
sRANKL. Although an appropriate drug delivery system into 
Figure 7
Impairment of osteoclastogenesis and NFAT2 induction by NFAT1 overexpression in the spleen cells of TRAP-DN–c-Jun TG mice. (A) Spleen cells 
isolated from wild-type littermates or TRAP-DN-TG (TG) mice were infected with control or constitutively active NFAT1 retrovirus, and cultured for 7 
days in the presence of M-CSF. TRAP+ multinucleated osteoclast-like cells were counted. (B) Spleen cells isolated from WT littermates or TG mice 
were infected with control or constitutively active NFAT1 retrovirus and cultured for 5 days in the presence of M-CSF. Cell lysates were analyzed by 
immunoblotting using anti-NFAT2 or anti–β-actin antibody. (C) Spleen cells isolated from WT littermates or TG mice were cultured for 5 days in the 
presence of M-CSF alone or both M-CSF and sRANKL. Cell lysates were analyzed by immunoblotting using anti-NFAT2 or anti–β-actin antibody.
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osteoclast progenitor cells must be developed, the peptide could 
be a useful and powerful agent for bone diseases associated with 
bone destruction by osteoclasts.
In conclusion, we have established an essential role for c-Jun sig-
naling in RANKL-induced osteoclast differentiation. We have also 
shown the crucial role of c-Jun in the regulation of expression and 
function of the NFAT family, which is important for osteoclasto-
genesis. Thus, we believe that these findings provide new insights 
into the molecular basis of osteoclastogenesis and a rationale for 
development of novel therapeutic agents for bone diseases associ-
ated with excessive and progressive osteoclastic bone resorption.
Methods
Cell and reagents. A monocytic cell line, RAW264, and COS-7 cell line 
were purchased from the RIKEN cell bank (Tsukuba, Ibaraki, Japan), 
and cultured in α-MEM containing 10% FCS (HyClone Laboratories, 
Logan, Utah, USA). sRANKL and M-CSF were purchased from Pepro-
Tech EC Ltd. (Rocky Hill, New Jersey, USA) and Green Cross Corp. 
(Osaka, Japan), respectively. Anti-JNK1, anti–phospho-JNK, anti–phos-
pho–c-Jun, and anti–phospho–ATF-2 antibodies were purchased from 
Cell Signaling Technology, Inc. (Beverly, Massachusetts, USA). Anti–c-
Jun, anti–c-Fos, anti-NFAT1, anti-NFAT2, anti-MKK7, anti–ATF-2, and 
anti–β-actin antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, California, USA).
Constructs and transfection. Dominant-negative c-Fos cDNA (31) and an 
NFATx3 luciferase construct (32) were gifts from Charles Vinson (Nation-
al Cancer Institute, Bethesda, Maryland, USA) and David J. McKean 
(Mayo Clinic, Rochester, Minnesota, USA), respectively. c-Jun cDNA was 
obtained from the RIKEN gene bank (Tsukuba, Ibaraki, Japan). NFAT1 
cDNA, NFAT2 cDNA, GFP-VIVIT construct, JNK1 cDNA, MKK7-JNK1 
cDNA, AP-1 luciferase construct, and the TRAP gene promoter have been 
described previously (16, 33, 34). To generate a dominant-negative mutant 
form of c-Jun (14), a PCR product that encoded the C-terminal domain of 
c-Jun (amino acids 123–334) lacking the transactivation domain was syn-
thesized and then subcloned into pcDNA3 (Invitrogen Corp., Carlsbad, 
California, USA) tagged with a Flag epitope in the N terminus. To gen-
erate dominant-negative JNK1, Lys55 of JNK1 was point-mutated into 
methionine by performing in vitro mutagenesis. To generate a dominant-
negative mutant of ATF-2 (35), a PCR product that encoded the C-termi-
nal domain of ATF-2 (amino acids 108–505) lacking the transactivation 
domain was synthesized and then subcloned into pcDNA3 (Invitrogen 
Corp.) tagged with a Myc epitope in the N terminus. The sequences of 
these mutants were confirmed by DNA sequence analysis. Transfection 
of RAW264 cells was carried out using Superfect (QIAGEN Inc., Valencia, 
California, USA) according to the manufacturer’s protocol.
Generation and analysis of transgenic mice. Dominant-negative c-Jun cDNA 
tagged with a Flag epitope was fused to 1.8 kb of the mouse TRAP gene 
promoter (16, 17). The transgenic mice were generated by pronuclear injec-
tion methods into mouse strain BDF1 (17). Genomic DNA isolated from 
the tail was analyzed by PCR and Southern blotting analysis using specific 
primers or the probes for the transgene, respectively. The expression of 
transgene was also confirmed by RT-PCR analysis. Bones were fixed in 10% 
buffered formalin, decalcified, and subjected to staining with H&E or for 
TRAP activity (17). Spleen cells isolated from wild-type or TRAP-DN–c-Jun 
TG mice were analyzed by the in vitro osteoclast differentiation assay (11). 
All the experiments were performed with sex- and age (4- to 6-week-old)-
matched mice under protocols approved by the Osaka University Graduate 
School of Dentistry animal care committee.
RT-PCR analysis. Total RNA was isolated from brain, kidney, liver, lung, or 
spleen cells, which were cultured in the absence or presence of M-CSF and 
sRANKL, and treated with RNase-free DNase (Wako Pure Chemicals Indus-
tries, Osaka, Japan). After denaturation of the total RNA at 70°C for 10 min-
utes, cDNAs were synthesized with oligo-dT primer and reverse transcriptase 
(QIAGEN Inc.). PCR amplification was performed by using specific primers 
for dominant-negative c-Jun tagged with a Flag epitope (forward primer: 5′-
AAGGACGATGATGACAAGGG-3′; reverse primer: 5′-AGTTGCTGAGGTT-
GGCGTAG-3′). PCR products were loaded onto agarose gels and stained with 
ethidium bromide. After PCR products were subcloned into TA-cloning vec-
tor (Invitrogen Corp.), DNA sequences of PCR products were determined.
Osteoclast differentiation in vitro. Bone marrow cells or spleen cells were iso-
lated from C57BL/6 mice (Nihon SLC Co., Hamamatsu, Shizuoka, Japan) 
and incubated with M-CSF (30 ng/ml) and sRANKL (100 ng/ml) for 6 
days (11). After 6 days, the cells were analyzed by TRAP staining (11), and 
TRAP+ multinucleated cells were counted as osteoclasts (11). BMMΦ cells 
were generated as described (18) and incubated in the presence of sRANKL 
(100 ng/ml) and M-CSF (30 ng/ml) for 6 days; then, the TRAP+ multinucle-
ated osteoclast-like cells were counted. RAW264 cells were incubated in the 
presence of sRANKL (20 ng/ml) for 6 days, and the TRAP+ multinucleated 
osteoclast-like cells were counted.
Osteoblast differentiation in vitro. The calvariae were isolated from 2- or 3-
day neonatal mice and digested with 0.1% collagenase (Wako Pure Chemi-
cals Industries) and 0.2% dispase (Invitrogen Corp.) for 7 minutes at 37°C. 
The digested calvariae were sequentially digested four times with 0.1% 
collagenase and 0.2% dispase for 7 minutes at 37°C. The last three groups 
of fractionated cells were collected and used as the primary osteoblasts. 
The cells were incubated with 100 ng/ml bone morphogenetic protein-2 
(BMP2) for 7 days, and determined by alkaline phosphatase (ALP) analysis 
as described previously (36).
Nonspecific esterase staining. Spleen cells isolated from mice were cul-
tured with M-CSF (10 ng/ml) for 6 days and stained by nonspecific 
esterase (NSE) staining kit (Sigma-Aldrich, St. Louis, Missouri, USA) 
according to the manufacturer’s protocol (8).
Immunoblotting analysis. The cell lysates or nuclear extracts were isolated 
from BMMΦ or RAW264 cells, and protein concentration was determined 
as previously described (37). Equivalent amounts of protein were loaded 
for SDS-PAGE, and immunoblotting was performed using specific anti-
bodies for JNK1, c-Jun, c-Fos, phospho-JNK, phospho–c-Jun, NFAT1, 
NFAT2, β-actin, and Myc epitope. In all immunoblotting analyses, we 
also confirmed that equal amounts of proteins were loaded by staining 
the transferred membranes with Ponceau S.
Generation of adenovirus. The recombinant adenovirus carrying NFAT1, 
NFAT2, GFP-VIVIT, c-Jun, c-Fos, or the dominant-negative form of JNK1, 
c-Jun, c-Fos, or ATF-2 was constructed by homologous recombination 
between the expression cosmid cassette and the parental virus genome in 
293 cells as previously described (38). The viruses were confirmed to retain 
no proliferative activity in the cells other than 293 cells, because they lack 
crucial regions for proliferation of adenovirus, E1A, and E1B (39). Titers of 
the viruses were determined using the modified point assay (39).
Generation of retrovirus. A retrovirus packaging cell line, platinum-E (Plat-E) 
(40), was transfected with a retrovirus vector, pMXs (40), carrying constitu-
tively active NFAT1 cDNA. The cultured media were collected 48 hours after 
transfection and stored as retrovirus stocks. Spleen cells were cultured in the 
presence of 30 ng/ml M-CSF for 4 days and subsequently infected with retro-
virus in the presence of polybrene (4 μg/ml) (Sigma-Aldrich) for 4 hours.
Reporter assay. The luciferase reporter constructs driven by the TRAP gene 
promoter or AP-1 or NFAT-responsive elements were described previously (16, 
32, 34). Transfection and luciferase assay were performed as described (34).
Oligonucleotide pull-down assay. Nuclear extracts were incubated with 
biotinylated oligonucleotide containing the NFAT-binding element 
present in the TRAP gene promoter (5′-AATCCTCGGAGAAAATGCAT-
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CATCTTTCC-3′) for 2 hours. Interaction of the oligonucleotides with 
NFAT1 protein was determined by immunoblotting using anti-NFAT1 
antibody as described previously (37).
Immunocytochemistry. Cells were washed three times with ice-cold PBS 
and fixed with 3.8% paraformaldehyde-PBS, permeabilized by incubation 
for 15 minutes with 0.1% Triton-PBS. The cells were blocked with 1% BSA-
PBS, incubated with anti-NFAT1 antibody for 2 hours, and washed six 
times with 0.1% Triton-PBS, and finally incubated with Rhodamine-con-
jugated anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories 
Inc., West Grove, Pennsylvania, USA). The cells were extensively washed 
with PBS and visualized using a fluorescence microscope (Carl Zeiss Vision 
GmbH, Hallbergmoos, Germany).
Generation of siRNA. siRNA constructs were generated in a retroviral vec-
tor pSINsi-H1 (Takara Bio Inc., Otsu, Shiga, Japan). The target sequences 
are as follow: mouse MKK7, 5′-GGAAGAGAATAAGCGCATT-3′ (41); 
mouse c-Jun, 5′-GTGCCTACGGCTACAGTAA-3′; luciferase, 5′-GTTG-
GCACCAGCAGCGCAC-3′. These siRNA constructs were transfected into 
Plat-E cells, and the retroviruses containing the siRNA were infected into 
mouse spleen cells as described earlier.
Statistical analysis. Data were analyzed by ANOVA and represent mean 
± SD (n = 4). All experiments were performed at least three times with 
identical results.
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